Skip to main content

Table 2 ANOVA results for all FMD variables

From: Acute effects of Nitrosigine® and citrulline malate on vasodilation in young adults

VariablePre-SupplementPost-Supplementp-value Supplement x Time Interactionp-value Supplement Effect
Flow-Mediated Dilation (%)
 Citrulline Malate7.15 ± 2.449.60 ± 2.72< .001< .001a
 Nitrosigine8.00 ± 3.1410.48 ± 2.63< .001a
 Placebo8.01 ± 2.907.87 ± 2.83.76b
Allometric Scaled FMD %
 Citrulline Malate7.09 ± 1.808.85 ± 1.98< .001< .001a
 Nitrosigine7.65 ± 2.169.47 ± 1.84< .001a
 Placebo7.69 ± 2.177.65 ± 2.07.90b
AUC Hyperemic Shear Rate to Maximum (∫ sec−1)
 Citrulline Malate164,109 ± 175,726269,706 ± 217,793.30.01a
 Nitrosigine245,539 ± 190,582288,877 ± 199,491.29b
 Placebo318,179 ± 205,705311,804 ± 224,332.92b
Maximum Shear Rate (sec−1)
 Citrulline Malate771.97 ± 310.45786.70 ± 253.42.86.75a
 Nitrosigine812.08 ± 376.58790.26 ± 268.38.76a
 Placebo918.25 ± 490.64914.91 ± 367.76.99a
  1. Note. FMD flow-mediated dilation. Values are reported as mean + SD. Values with different letters represent statistically significant values